161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer

Background

The SCOPE gastrointestinal (GI) cancers program aimed to gather insights on real-world management of GI cancers. We report practice patterns for patients (pts) with resectable pancreatic cancer (PaCa) and explore factors driving treatment (Tx) decisions.

Methods

An international panel of expert GI oncologists developed the SCOPE GI cancer survey. Healthcare professionals (HCPs) involved in management of PaCa were presented with a hypothetical pt case and asked about first- (1L) and second- (2L) line Tx choices. Data were collected at in-person or virtual meetings.

Results

Between July 2021 and December 2022, 293 HCPs from Japan and 469 HCPs from Europe and Argentina (ex-Japan) participated. In Japan, 51% of HCPs were internists (medical oncologists, oncologists, gastroenterologists) and 49% were surgeons; the majority of ex-Japan HCPs were medical oncologists (85%). Participants were asked how they would treat a pt with resectable stage II mPaCa who had relapsed after a 5-month Tx-free interval following adjuvant S-1 (Japan) or adjuvant mFOLFIRINOX (ex-Japan). The majority favored Gem-NabP as 1L Tx (70% in Japan, 85% ex-Japan), as they wanted to improve overall survival (OS; 51% in Japan, 70% ex-Japan) and in Japan to shrink the tumor (21%); in Japan, 27% of HCPs would also consider Tx with FOLFIRINOX/mFOLFIRINOX (vs 3% ex-Japan). In the 2L, the preferred Tx was Nal-Iri + 5-FU–LV (76% in Japan, 84% ex-Japan); the main reason for choosing this Tx was improving OS (59% in Japan, 43% ex-Japan) and preserving quality of life by ex-Japan HCPs (28% vs 12% Japan). Overall, 72% of HCPs (in Japan and ex-Japan) rated performance status as the key consideration when choosing 2L Tx.

Conclusions

For HCPs in Japan and ex-Japan, the preferred 1L Tx for pts with resectable PaCa whose disease is reaching the metastatic stage was Gem-NabP, and Nal-Iri + 5-FU–LV was the most favored 2L Tx for pts with progression on Gem-based regimens. These Tx decisions are in line with Asian and European guidelines. For all HCPs, improving OS was the main reason for these Tx choices. Regardless of geographic location, performance status was considered the key factor in selecting a 2L Tx.

Clinical trial identification

Editorial acknowledgement

Medical writing support was provided by Joanne Franklin, PhD, CMPP, from Aptitude Health, The Hague, the Netherlands, and funded by Les Laboratoires Servier, France.

Legal entity responsible for the study

Les Laboratoires Servier.

Funding

Has not received any funding.

Disclosure

T. Fujii: Financial Interests, Personal, Financially compensated role, Honoraria: Taiho, Yakult Honsha; Financial Interests, Institutional, Research Funding, Research Funding: Lilly, Terumo, Taiho, Daiichi Sankyo, Gunze Medical. G. Prager: Financial Interests, Personal, Advisory Board: Merck, Amgen, Servier, Bayer, Pierre Fabre, CECOG, Daiichi Sankyo Austria, AstraZeneca; Financial Interests, Personal, Invited Speaker: Roche, Sanofi, Lilly, BMS, MSD; Financial Interests, Institutional, Local PI: Incyte, servier, BMS, Novartis. S. Boeck: Financial Interests, Personal, Financially compensated role, Speakers Honoraria or Advisory Board: AstraZeneca, BMS, Incyte, Janssen-Cilag, MSD, Servier; Financial Interests, Institutional, Research Funding, Research Funding: Celgene. D. Santini: Financial Interests, Personal, Advisory Role, Consultant or Advisory Role: Roche, Merck Serono, Servier, Amgen, Bayer, Lilly, Eisai, MSD, BMS, Janssen, Sanofi, Incyte, Astellas. D.P. Modest: Financial Interests, Personal, Invited Speaker: Amgen, Servier, Merck, Onkowissen, MSD, BMS, AstraZeneca, Pierre Fabre, Lilly, Cureteq, GSK, Seagen, Medison, COR2ED, JE, 21up; Financial Interests, Personal, Advisory Board: Amgen, Servier, Merck, MSD, BMS, Incyte, Takeda, G1, Onkowissen, Pierre Fabre, AstraZeneca; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Coordinating PI: Servier. F. Rivera: Financial Interests, Personal, Advisory Board, Consultant or Advisory Role: Roche, Merck Serono, Amgen, MSD, BMS, Lilly, Celgene, Sanofi-Aventis, Servier, AstraZeneca, Bayer; Financial Interests, Institutional, Research Funding, Research Funding: Servier, Roche, Merck Serono, Amgen, MSD, Lilly, Celgene, Sanofi-Aventis, Bayer; Financial Interests, Personal, Invited Speaker, Speaker: Roche, Merck Serono, Amgen, MSD, BMS, Lilly, Celgene, Sanofi-Aventis, Servier, Bayer; Financial Interests, Institutional, Research Funding, Grant support: Amgen. J.M. Phelip: Financial Interests, Personal, Other, Travel grants: Merck Serono, Servier, Bayer, Raffo; Financial Interests, Institutional, Research Funding, Research grant: Merck Serono, Bayer, Servier; Financial Interests, Personal, Advisory Board: Merck Serono, Bayer, MSD, BMS, Servier. M.H. Dioca: Financial Interests, Personal, Advisory Role, Consultant or Advisory Role: Roche, Merck Serono, Amgen, MSD, BMS, Lilly, Sanofi-Aventis, Servier, AstraZeneca, Raffo, Bayer; Financial Interests, Institutional, Research Funding, Research Funding: Amgen; Financial Interests, Personal, Invited Speaker: Roche, Merck Serono, Amgen, MSD, Raffo, BMS, Lilly, Sanofi-Aventis, Servier, Bayer; Financial Interests, Institutional, Research Funding, Research Grant: Amgen. E. Smyth: Financial Interests, Personal, Invited Speaker: Amgen, Bristol Myers Squibb, Imedex, Merck, Novartis, Prova Education, Servier, TouchIME, Elsevier, Peervoice, Cor2Ed, Daiichi Sankyo; Financial Interests, Personal, Other, TSC: Amgen; Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, Bristol Myers Squibb, Bristol Myers Squibb, My Personal Therapeutics, Novartis, Roche, Servier, Zymeworks, Viracta; Financial Interests, Personal, Other, IDMC: BeiGene, Zymeworks; Financial Interests, Personal, Other, IDMC chair: Everest Clinical Research; Financial Interests, Personal, Officer: EORTC GI Clinical Trials Group; Financial Interests, Institutional, Local PI: Daiichi Sankyo, Merus, Basilea, MSD, Mirati; Financial Interests, Institutional, Coordinating PI: Roche, AstraZeneca, Amgen; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb; Non-Financial Interests, Personal, Leadership Role, Trustee: UK & Ireland Oesophagogastric Group (UKIOG). A. Zaanan: Financial Interests, Personal, Advisory Role, Consultant or Advisory Role: Amgen, Astellas, Merck, Roche, Sanofi, Servier, Baxter, MSD, BMS, Pierre Fabre, Havas Life, Alira Health, Zymeworks, AstraZeneca, Daiichi Sankyo. H.S. Wasan: Financial Interests, Personal, Advisory Board, Advisory Boards and Invited Speaker: Incyte, Pierre Fabre, Servier, Bayer, Roche/Genentech/ FM AG, SIRTEX medical ERYTECH, Celgene, Array BioPharma, Merck KGaA: BMS; Financial Interests, Personal, Steering Committee Member, Trial steering committee and advisory: Zymeworks; Financial Interests, Personal and Institutional, Coordinating PI, Trial PI steering committee and advisory: Sirtex Medical; Financial Interests, Personal, Other, Consultancy for Submission for UK approval (BSI): ONCOSL; Non-Financial Interests, Personal, Advisory Role, Trial steering committee: Pfizer; Non-Financial Interests, Personal, Advisory Role, UK NICE submission: Bayer, Pierre Fabre. J. Furuse: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical, Bayer, Eisai, Eli Lilly Japan, MSD, Yakult Honsha, Chugai Pharma, Novartis Pharma, AstraZeneca, Pfizer, Takeda, Taiho Pharmaceutical, Sannofy, Mylan EPD, EA Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Teijin pharma, Servier Japan, Incy; Financial Interests, Personal, Advisory Board: Fuji film, Mudi Pharma, Onco Therapy Science, Merck Bio, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Chugai Pharma, Astellas, AstraZeneca, Takara bio, Delta-Fly-Pharma, Incyte Japan; Financial Interests, Institutional, Research Grant: Ono Pharmaceutical, MSD, Merck Bio, J-Pharma, Taiho Pharmaceutical, Takeda, Chugai Pharma, AstraZeneca, Yakult Honsha, Eisai, Daiichi Sankyo, Mochida, Sanofy, Sumitomo Dainippon Bayer, Astellas, Incyte Japan; Financial Interests, Personal, Steering Committee Member: Merck Bio, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Astellas, AstraZeneca, Incyte Japan.